Monday, Jan 21, 2002
South San Francisco, Calif. -- January 21, 2002 --Genentech, Inc. (NYSE: DNA) announced today that it has been named by FORTUNE Magazine as one of the "100 Best Companies To Work For" for the fourth consecutive year. Genentech moved up the list to number 59 from number 76 last year. The complete list of companies will appear in the February 4, 2002, issue of the magazine.
"We are very honored that Fortune magazine has recognized Genentech as one of the "100 Best Companies To Work For" again this year," said Arthur D. Levinson, Ph.D., Genentech chairman and chief executive officer. "Our employees are critical to our success and we are proud to foster an environment that attracts, retains and rewards exceptional people."
FORTUNE screened a broad range of companies for its list. Genentech, along with the other companies on the list, was chosen based on answers 250 random employees gave to 56 questions on the Great Place to Work Trust Index survey, conducted by the Great Place to Work Institute in San Francisco. FORTUNE also reviewed company newsletters, employee handbooks and videos. In addition, the magazine gathered information about the impact the September 11th terrorist attacks had on the company and evaluated the company's subsequent responses to employees.
The company's extensive benefits include an adoption assistance program, a large corporate child care center, a six-week paid sabbatical after six years and flexible work arrangements. Genentech also offers all of its nearly 5,000 employees an employee stock purchase plan, eligibility for stock options and on-the-spot bonuses for exceptional work. Other benefits include health seminars and screenings, free commuter shuttles, a company-sponsored fitness facility, long-term care insurance, an on-site hair salon, pet insurance, take-home meals, a concierge service and travel services.
Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #